Alembic Pharma Gets US FDA Approval For Lastacaft Ophthalmic Solution
Alembic Pharmaceuticals Limited has received tentative approval from the US Food & Drug Administration (FDA) for its abbreviated new drug application (ANDA) alcaftadine ophthalmic solution, 0.25%.The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Lastacaft ophthalmic solution, 0.25%, of Allergan, Inc.Alcaftadine ophthalmic solution is an H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.Alcaftadine ophthalmic solution, 0.25% has an estimated market size of US$ 7 million for twelve months ending December 2019, according to IQVIA.Alembic has a cumulative total of 120 ANDA approvals (107 final approvals and 13 tentative approvals) from US FDA
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!